High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

  • Published on 08/02/2024
  •  Reading time: 6 min.

Furuya Kei 1, Nakajima Masao 1, Tsunedomi Ryouichi 1, Nakagami Yuki 1, Xu Ming 1, Matsui Hiroto 1, Tokumitsu Yukio 1, Shindo Yoshitaro 1, Watanabe Yusaku 1, Tomochika Shinobu 1, Maeda Noriko 1, Iida Michihisa 1, Suzuki Nobuaki 1, Takeda Shigeru 1, Hazama Shoichi 1, Ioka Tatsuya 2, Hoshii Yoshinobu 3, Ueno Tomio 4, Nagano Hiroaki 1

1 https://ror.org/03cxys317 Department of Gastroenterological, Breast and Endocrine Surgery Yamaguchi University Graduate School of Medicine 1-1-1 Minami-Kogushi 755-8505 Ube Yamaguchi Japan
2 https://ror.org/02dgmxb18 Oncology Center Yamaguchi University Hospital 755-8505 Ube Yamaguchi Japan
3 https://ror.org/02dgmxb18 Department of Diagnostic Pathology Yamaguchi University Hospital 755-8505 Ube Yamaguchi Japan
4 https://ror.org/059z11218 Department of Digestive Surgery Kawasaki Medical School 701-0192 Kurashiki Okayama Japan


Background To improve the prognosis of patients with metastatic colorectal cancer (mCRC), investigating predictive biomarkers of their prognosis and chemotherapeutic responsiveness is necessary. This study aimed to analyze the clinical significance of serum proteinase-3 (PRTN3) as a predictor for prognosis and chemosensitivity, especially to bevacizumab therapy, in mCRC.
Methods This single-center retrospective observational study enrolled 79 patients with...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology

More articles

From peer-reviewed journals in Oncology